Tests a stem cell transplant with lower-intensity treatment for bone marrow failure
Tests a stem cell transplant in people with severe aplastic anemia and related conditions.
Key facts
- Who runs it
- Masonic Cancer Center, University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 5 Jun 2024
- Expected to end
- 1 May 2036
- Type of study
- Interventional, 2 groups
- Treatments tested
- Rituximab
- Rabbit ATG
- Cyclophosphamide
- Fludarabine
- Total Body Irradiation
- Cell Infusion
- Post-Transplant G-CSF
- Tacrolimus
- Mycophenolate Mofetil
- Record updated
- 3 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with severe aplastic anemia, PNH, acquired pure red cell aplasia or acquired amegakaryocytic thrombocytopenia. They would receive a bone marrow or stem cell transplant with lower-intensity conditioning.
- Age
- 0 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Severe aplastic anemia with refractory low blood counts, or PNH, acquired pure red cell aplasia or acquired amegakaryocytic thrombocytopenia with refractory low blood counts. Early myelodysplastic features with bone marrow blasts <5% are allowed. A second transplant after graft failure is also allowed.
- Earlier treatment
- No history of MDS/AML before treatment. Prior radiation therapy must not be excessive for the planned low dose total body irradiation.
- Biomarker or test result
- For PNH, aPRCA and aAT: bone marrow shows 1 to 3-lineage aplasia, or a PNH clone in the blood of at least 10%. After graft failure, donor chimerism in blood or marrow is below 5%.
Main reasons for not taking part
- Pregnant, breastfeeding or planning pregnancy during the study
- Uncontrolled infection
- Moderate or severe portal fibrosis or cirrhosis on biopsy
- Inherited bone marrow failure disorder such as Fanconi anemia, unless the principal investigator approves
- Advanced MDS (bone marrow blasts >5%) or acute myeloid leukemia
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Idiopathic Severe Aplastic Anemia (SAA), characterized by one of the following:; Refractory cytopenia(s), with 1+ of the following:; Platelets <20,000/uL or transfusion dependent; Absolute neutrophil count <500/uL without hematopoietic growth factor support; Absolute reticulocyte count <60,000/uL AND bone marrow cellularity <50% (with < 30% residual hematopoietic cells); Early myelodysplastic features (bone marrow (BM) blasts <5%), without history of MDS/AML pre-treatment; Idiopathic SAA with post-HCT graft failure (blood/marrow donor chimerism <5%) requiring a 2nd allogeneic HCT
- Paroxysmal Nocturnal Hemoglobinuria (PNH), including AA-PNH overlap syndrome, acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT), characterized by one of the following:; Refractory cytopenia(s), with 1+ of the following:; Platelets <20,000/uL or transfusion dependent; Absolute neutrophil count <500/uL without hematopoietic growth factor support; Absolute reticulocyte count <60,000/uL or red cell transfusion dependent AND Bone marrow evidence of 1 to 3-lineage aplasia OR peripheral blood PNH clone >/= 10%; Early myelodysplastic features (bone marrow (BM) blasts <5%) without history of MDS/AML pre-treatment; Idiopathic PNH, aPRCA, or aAT with post-HCT graft failure (blood/marrow donor chimerism <5%) requiring a 2nd allogeneic HCT
- Adequate organ function within 30 days of conditioning regimen
Who cannot take part
- Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol
- Uncontrolled infection
- Known allergy to any of the study components
- Diagnosis of an inherited bone marrow failure disorder such as Fanconi anemia, Telomere biology disorder, or Schwachman-Diamond syndrome, unless reviewed by the principal investigator and deemed appropriate for this approach (e.g. GATA2 deficiency)
- Advanced myelodysplastic syndrome (MDS; BM blasts >5%) or acute myeloid leukemia
- Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
- Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study
- Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment
- Evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 75 years old?
Where in United States
- University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Meera Srikanthan, MDTaking people
About the trial
What the trial wants to find out
A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.
The 2 groups in the trial
- Arm A: No clonal hematopoiesisTreatment being tested
Participants 25 years of age and younger with no clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.
Treatment: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, and Mycophenolate Mofetil
- Arm B: Clonal hematopoiesisTreatment being tested
Participants 25-75 years old and/or with clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.
Treatment: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, and Mycophenolate Mofetil
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Plain-language title
- Tests a stem cell transplant with lower-intensity treatment for bone marrow failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06412497, who can take part
- Record updated
- 3 June 2026